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Editorial Comment 
Pulmonary Embolism 
Thrombolysis: A Clarion Call for 
International Collaboration* 
SAMUEL Z. GOLDHABER, MD, FACC 
Boston, Massachusetts 
Cardiologists and others have struggled for the past 25 years 
to find optimal ways of testing thrombolytic therapy for 
pulmonary embolism. The challenge is daunting because 
appropriate subjects are difficult to identify and suitable end 
points for evaluation are not clear-cut. Although venous 
thromboembolism is the third most common cardiovascular 
disease (after acute ischemic syndromes and stroke), interest 
in this condition is diffused among many subspecialties. 
Therefore, the urge to confront the special problems in 
pulmonary embolism trial design and execution has been 
attenuated. This neglect is particularly tragic because the 
death rate from pulmonary embolism, unlike that from most 
other cardiovascular diseases, has not declined at all during 
the past generation (1). 
The present study. Despite these obstacles, Professor 
Marc Verstraete organized 12 centers in five European 
countries to undertake a randomized, double-blind, double-
dummy trial to compare two Food and Drug Administration 
(FDA)-approved regimens for pulmonary embolism throm-
bolysis: 100 mg of recombinant tissue-type plasminogen 
activator (rt-PA) administered as a continuous infusion over 
2 h versus 4,400 U/kg of urokinase as a bolus dose, followed 
by 4,400 U/kg per h for 12 h (2). In the trial reported in this 
issue of the Journal (2), the investigators took a novel and 
clever approach. They chose as their principal end point a 
reduction in total pulmonary resistance, defined as pulmo-
nary artery mean pressure divided by cardiac index, because 
they believed that this measurement would provide a more 
sensitive index of pulmonary revascularization than would 
pulmonary angiography. Nevertheless, they hedged their 
bets by performing bilateral pulmonary arteriography before 
and after treatment. This latter strategy, reminiscent of 
pulmonary embolism thrombolysis trials conducted in the 
1970s, was associated with an unacceptably high rate of 
pericardial perforation and hemorrhage, probably because of 
protocol violations caused by the use of stiff rather than 
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flexible catheters. By the midpoint of the trial, 5 of 63 
patients had pericardial perforation and hemorrhage. Three 
of these patients developed pericardial tamponade, and two 
died from this complication. After 27 months of recruitment, 
the Data Monitoring and Ethical Committee recommended 
termination of the study because of this grave problem. 
Despite the initial sample size calculations, the trial 
yielded statistically significant results even though it was 
only half the originally planned size. Recombinant tissue-
type plasminogen activator caused a more rapid decrease in 
total pulmonary resistance than did urokinase during the 
initial 2 h of therapy. However, by 12 h, the effects of 
urokinase and rt-PA were equivalent and total pulmonary 
resistance was reduced to 50% of baseline values in both 
treatment groups. Angiographic improvement, assessed 12 
to 18 h after initiation of therapy, was the same in both 
groups. All five cases of pericardial perforation occurred in 
patients treated with rt-PA (p = 0.17; two-tailed Fisher's 
exact test); the rate of all major hemorrhagic complications 
did not differ between the two groups. 
Comparison with multicenter American trial. This Euro-
pean Cooperative Study Group (ECSG) trial provides valu-
able data on the effect of two FDA-approved regimens for 
pulmonary embolism thrombolysis. The results agree with 
and complement our findings (3) in a multicenter American 
trial reported in 1988. The patients with pulmonary embo-
lism in the European trial were, on average, as ill as the 
patients in our trial; initial right heart catheterization dem-
onstrated comparable levels of pulmonary hypertension in 
patients in the two trials. Both trials enrolled a high propor-
tion of patients 11 to 30 days postoperatively, suggesting that 
efforts to prevent postoperative pulmonary embolism are 
probably too lax on both sides of the Atlantic. We compared 
the effects of 2 h of rt-PA with those of 24 h of urokinase. 
Our principal end points were improvement in clot lysis at 
2 h (assessed with unilateral angiography) and pulmonary 
perfusion at 24 h assessed by perfusion lung scan. In our 
trial, rt-PA acted more rapidly than urokinase at 2 h, but the 
effects of the two drugs were similar by 24 h. We also found 
that rt-PA administered over 2 h caused fewer bleeding 
complications than did urokinase administered over 24 h. 
Fortunately, in our trial, no patient died from hemorrhagic 
problems, and there were no instances of pericardial perfo-
ration. In both trials, there was no difference in nadir 
fibrinogen levels between patients treated with rt-PA or 
urokinase. 
Future strategies. I know that some of the ECSG inves-
tigators have become discouraged by stumbling blocks im-
posed by clinical research in pulmonary embolism thrombol-
ysis; consequently, this prestigious and influential group 
may consider relinquishing its role in carrying out innovative 
pulmonary embolism trials. If these investigators choose this 
course, pulmonary embolism thrombolysis in Europe may 
revert to orphan status. My hope is that all investigators of 
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pulmonary embolism thrombolysis will move forward and 
focus on three exciting strategies that are just now emerging. 
First, we have reached the point where pulmonary angi-
ography is no longer required for every patient enrolled in a 
pulmonary embolism thrombolysis trial. This concept should 
be especially familiar and acceptable to cardiologists, who 
routinely treat patients with myocardial infarction with 
thrombolytic therapy but without mandatory coronary angi-
ography. In the Prospective Investigation of Pulmonary 
Embolism Diagnosis (PIOPED) study (4) published last year, 
patients with a high probability of pulmonary embolism on 
the basis of ventilation-perfusion lung scans and clinical 
findings had a 96% positive predictive value for pulmonary 
embolism at angiography. If pulmonary angiography is un-
dertaken, flexible rather than stiff catheters should be used, 
especially if patients will receive thrombolytic therapy (5). 
Second, recently published experimental (6) and clinical 
(7) pulmonary embolism studies suggest that more concen-
trated and shorter thrombolysis regimens may yield im-
proved efficacy and safety. Our collaborative group has just 
completed a trial comparing 100 mg of rt-PA over 2 h versus 
urokinase in a novel dosing regimen of 3 million U over 2 h, 
with the 1st 1 million U administered as a bolus over 10 min. 
We are now initiating an international trial (USA, Canada, 
Italy) in which we are comparing the 2-h FDA-approved 
dose of 100 mg of rt-PA over 2 h with a bolus dose of rt-PA 
(0.6 mg/kg over 15 min, with a maximal dose of 50 mg). We 
hypothesize that bolus rt-PA will be safer than rt-PA admin-
istered over 2 h and that efficacy will be comparable in both 
groups. 
Third, future trials need to test an optimal thrombolytic 
regimen followed by anticoagulation versus anticoagulation 
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alone to determine which patients with pulmonary embolism 
should receive thrombolytic therapy. Such studies will need 
to focus on relevant clinical end points such as reduction of 
mortality, recurrent pulmonary embolism and chronic pul-
monary hypertension. More emphasis is needed on deter-
mining whether differences emerge in the quality of life 
between patients who receive thrombolytic therapy com-
pared with those who receive anticoagulation alone. Such 
trials will require sample sizes of many hundreds of patients. 
To carry out this plan, a clarion call for international 
collaboration must be answered. 
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